Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis

Overview

This modular Program will first confirm the safety and efficacy of Paromomycin IM Injection when given to an expanded population in the outpatient setting in experienced VL centers and subsequently evaluate the effectiveness of an expanded access model of providing Paromomycin IM Injection to progressively more resource-constrained clinics in Bihar, India.

Full Title of Study: “A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2008

Detailed Description

Safe, effective, and affordable treatments for visceral leishmaniasis (VL) that are widely available to the poorest population of rural India where the disease is endemic are urgently needed. Resistance to antimonials, which have historically been the first line of treatment for VL in Bihar and adjoining states, is a major problem. Other available treatments are limited by their high cost, toxicity, or contraindications in certain populations. Paromomycin IM Injection was approved for the treatment of VL in August 2006 by the Drug Controller General of India (DCGI). The study is designed to establish a Phase 4 Access Program in a modular, stepwise fashion (Modules 1 to 3). The study will first confirm the safety and efficacy of Paromomycin IM Injection in an expanded VL population treated as an outpatient in experienced centers (Module 1); and then progressively extend the network of treatment facilities, the number and reach of the trained staff, and the implementation of the requisite logistics systems to rural Bihar (Modules 2 and 3). An expanded network of healthcare workers will be trained and supervised to make a preliminary diagnosis of VL; to make appropriate referrals to confirm the diagnosis of VL; to treat with Paromomycin IM Injection; and to assess patient safety and clinical response on an outpatient basis.

Interventions

  • Drug: Paromomycin sulfate
    • Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days

Arms, Groups and Cohorts

  • Experimental: A
    • Paromomycin IM Injection (approved product in India)

Clinical Trial Outcome Measures

Primary Measures

  • M1: Safety as measured by adverse events, serious adverse events, vital signs, and laboratory parameters.
    • Time Frame: M1: Approximately 6 months
  • M2&3: Program effectiveness as measured by specific criteria for healthcare workers, patients, and operational systems.
    • Time Frame: approximately 2.5 years

Secondary Measures

  • M1: Clinical cure as measured by temperature/hx of fever, spleen size decrease by at least 33% from baseline, and clinical assessment of treating physician.
    • Time Frame: M1: Approximately 6 months
  • M2 and M3: Clinical cure as measured by temperature/hx of fever, spleen size decrease, and clinical assessment of treating physician.
    • Time Frame: approximately 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed, newly diagnosed or relapsed visceral leishmaniasis Exclusion Criteria:

  • HIV infection, tuberculosis – Significant hematologic, renal or liver dysfunction – Malaria – Those unable to be treated as an outpatient.

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • PATH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • P K Sinha, MD, Principal Investigator, Rajendra Memorial Research Institute of Medical Sciences
    • T K Jha, MD, Principal Investigator, Kalazar Research Centre
    • C P Thakur, MD, Principal Investigator, Kala-azar Research Centre
    • Shyam Sundar, MD, Principal Investigator, Kala-azar Medical Research Centre
    • Devendra Nath, MD, Principal Investigator, Shrimati Hazari Maternity and Medical Care
    • Supriyo Mukherjee, MD, Principal Investigator, Research Centre for Diabetes, Hypertension and Obesity
    • Amrendra K Aditya, MD, Principal Investigator, Dr. A.K. Aditya Clinic

References

Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571-81.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.